A-LONG study of Elocate (Biogen/Sobi) published in Blood journal
Biogen Idec and Swedish Orphan Biovitrum AB announced that the detailed phase III data for the companies� investigational long-lasting recombinant factor VIII Fc fusion protein candidate Elocate were published online in Blood, the journal of the American Society of Hematology (ASH). Results from the A-LONG study showed that people with severe haemophilia A may achieve effective prevention or reduction of bleeding episodes with one or two prophylactic infusions a week.
See-"Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A." Blood blood-2013-10-529974; published ahead of print November 13, 2013, doi:10.1182/blood-2013-10-529974-Johnny Mahlangu, Jerry S. Powell, Margaret V. Ragni, et al.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.